Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer's disease: A meta-analysis 2015–2023
Abstract
Background Synaptic proteins are often used as markers for synaptic damage in non-clinical models of Alzheimer's disease (AD) and are known to be affected early in the disease in humans. Presynaptic protein loss has been shown to be especially strong in patients, though not all proteins and brain areas are affected equally. Objective To investigate whether presynaptic protein loss is similarly heterogenous in non-clinical AD models, a meta-analysis was conducted in rodent models of the disease. Methods PubMed, Embase, and Medline databases were searched for publications measuring presynaptic markers in AD rodent model brains between 2015–2023. A total of 1333 records arose from the searches, and these were screened for suitable studies. Meta-analyses on global presynaptic protein changes, protein-, area- and model-specific effects amongst others were performed on 184 studies. Studies employing proteomic approaches for protein quantification were analyzed separately from non-proteomic studies. Results Robust and significant global loss of presynaptic proteins was observed in these animal models. The effect size varied between different model types, with the greatest effects being observed in models in which either tau was genetically modified or where amyloid-β injection was used. The greatest severity was seen in hippocampal subregions and for proteins associated with the vesicle release machinery (SNARE proteins). Conclusions Proteomic studies confirmed that presynaptic…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.